CHICAGO (AP) — Patients with pancreatic cancer that hadn’t spread lived substantially longer on a four-drug combo than on a single standard cancer drug.
It’s a rare advance for a tough-to-beat cancer, and experts say it could be practice-changing for a small group of patients whose pancreatic cancer is diagnosed early enough to be removed by surgery.
Results were reported Monday at a medical meeting in Chicago.
The study tested folfirinox against the standard treatment, Gemzar. Folfirinox combines four chemotherapy drugs.
Two-thirds of patients given folfirinox were alive after three years versus half of those given Gemzar.
Nearly 500 patients in France and Canada were enrolled.
(Copyright (c) 2019 The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed.)